Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 15 for:    Idasanutlin

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02828930
Recruitment Status : Completed
First Posted : July 12, 2016
Last Update Posted : December 18, 2017
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
The purpose of this single-center, open-label, non-randomized study is to assess the excretion balance, pharmacokinetics, metabolism and absolute oral bioavailability of [14C]-labeled idasanutlin administered orally and [13C]-labeled idasanutlin administered intravenously in a single cohort of eligible participants. Participants will be screened for participation in this study within 21 days of receiving the first dose of study drug on Day 1. Treatment period will continue up to Day 28 after which participants will enter 28 day follow-up or the optional treatment extension of idasanutlin, depending on safety parameters and as per opinion of the Investigator.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Idasanutlin Drug: Placebo Drug: [13C]-radiolabeled Idasanutlin Drug: [14C]-radiolabeled Idasanutlin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics, Metabolism, and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Patients With Solid Tumors
Actual Study Start Date : September 8, 2016
Actual Primary Completion Date : June 19, 2017
Actual Study Completion Date : June 19, 2017

Arm Intervention/treatment
Experimental: Idasanutlin
On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
Drug: Idasanutlin
Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
Other Name: RO5503781

Drug: Placebo
Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.

Drug: [13C]-radiolabeled Idasanutlin
[13C]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.

Drug: [14C]-radiolabeled Idasanutlin
[14C]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.




Primary Outcome Measures :
  1. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Unlabeled Idasanutlin [ Time Frame: 0 Hour (hr) predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  2. Maximum Observed Plasma Concentration (Cmax) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  3. Area Under the Plasma Concentration Time-Curve From Time Zero to Extrapolated Infinite Time (AUC [0-inf]) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  4. Area Under the Plasma Concentration Time-Curve From Zero to the Last Measured Concentration (AUC[0-last]) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  5. Plasma Elimination Half-Life (t1/2) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  6. Plasma Apparent Elimination Rate Constant of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  7. Apparent Oral Clearance (CL/F) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  8. Renal Clearance (CLr) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  9. Apparent Volume of Distribution (Vz/F) of Unlabeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  10. Cumulative Amount Excreted in Urine of Unlabeled Idasanutlin [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  11. Cumulative Amount Excreted in Feces of Unlabeled Idasanutlin [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  12. Tmax of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  13. Cmax of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  14. AUC (0-inf) of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  15. AUC(0-last) of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  16. Plasma t1/2 of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  17. Plasma Apparent Elimination Rate Constant of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  18. CL/F of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  19. CLr of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  20. Vz/F of Idasanutlin Metabolite [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  21. Cumulative Amount Excreted in Urine of Idasanutlin Metabolite [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  22. Cumulative Amount Excreted in Feces of Idasanutlin Metabolite [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  23. Tmax of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55 minutes (min), 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  24. Cmax of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55 min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  25. AUC(0-inf) of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55 min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  26. AUC(0-last) of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  27. Plasma t1/2 of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  28. Absolute Oral Bioavailability of [13C]-Labeled Idasanutlin [ Time Frame: Oral administration: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose; IV administration: 0 hr predose, 5hr 55min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  29. Whole Blood and Plasma Cmax of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  30. Whole Blood and Plasma AUC(0-inf) of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  31. Whole Blood and Plasma AUC(0-last) of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  32. Whole Blood and Plasma Apparent Elimination Rate Constant of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  33. Cumulative Amount of Radioactivity Excreted in Urine as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  34. Cumulative Amount of Radioactivity Excreted in Feces as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]
  35. CL/F of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  36. Vz/F of [13C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 5hr 55min, 6hr, 6hr 5min, 6hr 10min, 6hr 15min, 6hr 30min, 7, 10, 24, 48, 96, 120, 144, 240 hrs postdose ]
  37. Whole Blood and Plasma Tmax of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr predose, 1, 3, 6, 7, 24, 48, 96, 120, 144, 240 hrs postdose ]
  38. Cumulative Amount of Radioactivity Excreted in Feces on Toilet Tissue as Percentage of Dosed Radioactivity of [14C]-Labeled Idasanutlin [ Time Frame: 0 hr (within 24 hrs of dosing), pooled sample collected over time interval: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, 144-168, 168-192, 192-216, 216-240, 240-264 hrs postdose ]

Secondary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline through 28 days after the last dose of study drug (maximum up to approximately 76 days) ]
  2. Palatability Assessment Questionnaire Score for Aqueous Dispersion of Idasanutlin [ Time Frame: 0 hr (pre-Day 11-dose), 0.5 hr, 1 hr, 1.5 hr, 2 hr, and 3 hr post-Day 11-dose ]
  3. Aftertaste Survey Questionnaire Score for Aqueous Dispersion of Idasanutlin [ Time Frame: 0 hr (pre-Day 11-dose), 0.5 hr, 1 hr, 1.5 hr, 2 hr, and 3 hr post-Day 11-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, at the discretion of the Investigator
  • Histologically or cytologically confirmed advanced malignancy, except leukemia and lymphoma
  • Measureable or evaluable disease by Response evaluation criteria in solid tumors (RECIST) version 1.1, with no more than a single active malignancy in the previous 3 to 5 years prior to the administration of study drug
  • Life expectancy of at least 12 weeks
  • Participants taking opioid analgesics for pain should be on a stable pain and palliative care bowel regimen for one month prior to the first dose of study medication
  • Adequate bone marrow, hepatic, and renal function
  • Agreement to remain abstinent or use contraceptive methods specified in the study

Exclusion Criteria:

  • History of any form of leukemia, except for Stage 0 - 1 chronic lymphocytic leukemia, not requiring treatment in addition to their underlying malignancy
  • Have received hormonal therapy within the two weeks prior to the first dose of study drug
  • Have pre-existing gastrointestinal disorders that may interfere with proper absorption of the drug
  • History of seizure disorders or unstable Central Nervous System metastases (participants with stable CNS metastases allowed)
  • Have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • Receive certain per protocol prohibited medications while on study. These medications must be discontinued 7 days prior to start of study drug
  • Have bone marrow disorders, electrolyte imbalance, infrequent bowel movements (less than once per 48 hours), coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia
  • Positive for human immunodeficiency virus currently receiving combination anti-retroviral therapy
  • Regular work with ionizing radiation or radioactive material or treated with radiotherapy within 3 weeks prior to the first dose of study drug
  • Refuse to potentially receive blood products and/or have a hypersensitivity to blood products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02828930


Locations
Layout table for location information
Hungary
Magyar Honvedseg Egeszsegugyi Kozpont
Budapest, Hungary, H-1134
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02828930    
Other Study ID Numbers: NP29910
RG7388 ( Other Identifier: Roche )
2015-002532-40 ( EudraCT Number )
First Posted: July 12, 2016    Key Record Dates
Last Update Posted: December 18, 2017
Last Verified: December 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms